Osteologix A/S

Osteologix develops pharmaceutical products for bone and cartilage disorders.

Osteologix was founded in 2003 as Nordic Bone A/S receiving venture capital funding from the Scandinavian venture fund Nordic Biotech K/S. In October 2004, the company was renamed in Osteologix and a US subsidiary was established.

Philip J. Young, CEO
Stephan Christgau, COO
Matthew M. Loar, CFO
Malene Weis, Manager of Clinical Development

Klaus Eldrup Jørgensen, MD
Philip J Young
Christopher B. Wood, MD
Christian Hansen, PhD
Florian Schönharting
Bobby W. Sandage Jr., PhD
Jeremy Curnock Cook

Leslie Z. Benet, PhD
Göran Samsioe, MD, PhD
Susan Greenspan, MD
Jens E.T. Andersen, PhD

Symbion Science Park
Fruebjergvej 3, box 4
2100 Copenhagen
Denmark
Phone: +45-39179730
Fax: +45-39179731

Osteologix’s lead agent is developed for prophylaxis and treatment of osteoporosis, but additional programmes are aiming at secondary indications in metabolic bone diseases and osteoarthritis.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.